Thromb Haemost 2015; 114(06): 1189-1198
DOI: 10.1160/TH15-01-0062
Cellular Haemostasis and Platelets
Schattauer GmbH

Polyphosphates form antigenic complexes with platelet factor 4 (PF4) and enhance PF4-binding to bacteria

Sven Brandt
1   ZIK HIKE – Centre of innovation competence “Humoral Immune Reactions in Cardiovascular Diseases“, Greifswald, Germany
,
Krystin Krauel
2   Institute for Immunology and Transfusion Medicine, Greifswald, Germany
,
Miriam Jaax
2   Institute for Immunology and Transfusion Medicine, Greifswald, Germany
,
Thomas Renné
3   Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
,
Christiane A. Helm
4   Institute for Experimental Physics, Greifswald, Germany
,
Sven Hammerschmidt
5   Department Genetics of Microorganisms, Interfaculty Institute for Genetics and Functional Genomics, Greifswald, Germany
,
Mihaela Delcea*
1   ZIK HIKE – Centre of innovation competence “Humoral Immune Reactions in Cardiovascular Diseases“, Greifswald, Germany
,
Andreas Greinacher*
2   Institute for Immunology and Transfusion Medicine, Greifswald, Germany
› Author Affiliations
Further Information

Publication History

Received: 21 January 2015

Accepted after major revision: 17 June 2015

Publication Date:
30 November 2017 (online)

Summary

Short chain polyphosphates (polyP) are pro-coagulant and pro-inflammatory platelet released inorganic polymers. The platelet chemokine platelet factor 4 (PF4) binds to lipid A on bacteria, inducing an antibody mediated host defense mechanism, which can be misdirected against PF4/heparin complexes leading to the adverse drug reaction heparin-induced thrombocytopenia (HIT). Here, we demonstrate that PF4 complex formation with soluble short chain polyP contributes to host defense mechanisms. Circular dichroism spectroscopy and isothermal titration calorimetry revealed that PF4 changed its structure upon binding to polyP in a similar way as seen in PF4/heparin complexes. Consequently, PF4/polyP complexes exposed neoepitopes to which human anti-PF4/heparin antibodies bound. PolyP enhanced binding of PF4 to Escherichia coli, hereby facilitating bacterial opsonisation and, in the presence of human anti-PF4/polyanion antibodies, phagocytosis. Our study indicates a role of polyP in enhancing PF4-mediated defense mechanisms of innate immunity.

* Shared senior authorship.


 
  • References

  • 1 Achbergerova L, Nahalka J. Polyphosphate-an ancient energy source and active metabolic regulator. Microb Cell Factories 2011; 10: 63.
  • 2 Gray MJ, Wholey WY, Wagner NO. et al. Polyphosphate is a primordial chaperone. Mol Cell 2014; 53: 689-699.
  • 3 Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-647.
  • 4 Ruiz FA, Lea CR, Oldfield E. et al. Human platelet dense granules contain poly-phosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-44257.
  • 5 Herzberg MC, Krishnan LK, Macfarlane GD. Involvement of Alpha(2)-Adrenoceptors and G-Proteins in the Modulation of Platelet Secretion in Response to Streptococcus-Sanguis. Crit Rev Oral Biol M 1993; 04: 435-442.
  • 6 Muller F, Mutch NJ, Schenk WA. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-1156.
  • 7 Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA. et al. Polyphosphate Is a Novel Pro-inflammatory Regulator of Mast Cells and Is Located in Acidocalcisomes. J Biol Chem 2012; 287: 28435-28444.
  • 8 Kornberg A, Rao NN, Ault-Riche D. Inorganic polyphosphate: A molecule of many functions. Annu Rev Biochem 1999; 68: 89-125.
  • 9 Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Intern J Hematol 2012; 95: 346-352.
  • 10 Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation. Blood 2012; 119: 5972-5979.
  • 11 Smith SA, Mutch NJ, Baskar D. et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
  • 12 Smith SA, Choi SH, Davis-Harrison R. et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-4359.
  • 13 Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-2816.
  • 14 Mutch NJ, Engel R, de Willige SU. et al. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010; 115: 3980-3988.
  • 15 Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-6970.
  • 16 Wat JM, Foley JH, Krisinger MJ. et al. Polyphosphate suppresses complement via the terminal pathway. Blood 2014; 123: 768-776.
  • 17 Nickel KF, Spronk HM, Mutch NJ. et al. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-3849.
  • 18 Lorenz B, Leuck J, Kohl D. et al. Anti-HIV-1 activity of inorganic polyphosphates. J Acq Immune Def Syndr Human Retrovirol 1997; 14: 110-118.
  • 19 Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost 2008; 06: 1750-1756.
  • 20 Smith SA, Choi SH, Collins JNR. et al. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120: 5103-5110.
  • 21 Wolpe SD, Cerami A. Macrophage Inflammatory Protein-1 and Protein-2 – Members of a Novel Superfamily of Cytokines. Faseb J 1989; 03: 2565-2573.
  • 22 Huang SS, Huang JS, Deuel TF. Proteoglycan Carrier of Human-Platelet Factor-4 – Isolation and Characterization. J Biol Chem 1982; 257: 1546-1550.
  • 23 Deuel TF, Keim PS, Farmer M. et al. Amino-Acid Sequence of Human Platelet Factor 4. Proc Natl Acad Sci USA 1977; 74: 2256-2258.
  • 24 Rucinski B, Niewiarowski S, James P. et al. Antiheparin Proteins Secreted by Human Platelets – Purification, Characterization, and Radioimmunoassay. Blood 1979; 53: 47-62.
  • 25 Kaplan KL, Broekman MJ, Chernoff A. et al. Platelet Alpha-Granule Proteins – Studies on Release and Subcellular-Localization. Blood 1979; 53: 604-618.
  • 26 Brandt S, Krauel K, Gottschalk KE. et al. Characterisation of the conformational changes in platelet factor 4 induced by polyanions: towards in vitro prediction of antigenicity. Thromb Haemost 2014; 112: 53-64.
  • 27 Krauel K, Weber C, Brandt S. et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood 2012; 120: 3345-3352.
  • 28 Jaax ME, Krauel K, Marschall T. et al. Complex formation with nucleic acids and aptamers alters antigenic properties of platelet factor 4. Blood 2013; 122: 272-281.
  • 29 Lo YM, Zhang J, Leung TN. et al. Rapid clearance of fetal DNA from maternal plasma. Am J Human Genet 1999; 64: 218-224.
  • 30 Krauel K, Potschke C, Weber C. et al. Platelet factor 4 binds to bacteria-inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378.
  • 31 Krauel K, Furll B, Warkentin TE. et al. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008; 06: 2160-2167.
  • 32 Krauel K, Hackbarth C, Furll B. et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119: 1248-1255.
  • 33 Kreimann M, Brandt S, Krauel K. et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124: 2442-2449.
  • 34 Bohm G, Muhr R, Jaenicke R. Quantitative-Analysis of Protein Far Uv Circular-Dichroism Spectra by Neural Networks. Protein Eng 1992; 05: 191-195.
  • 35 Juhl D, Eichler P, Lubenow N. et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
  • 36 Wiseman T, Williston S, Brandts JF. et al. Rapid Measurement of Binding Constants and Heats of Binding Using a New Titration Calorimeter. Anal Biochem 1989; 179: 131-137.
  • 37 Freire E, Mayorga OL, Straume M. Isothermal Titration Calorimetry. Anal Chem 1990; 62: A950-A959.
  • 38 Krauel K, Potschke C, Weber C. et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 2011; 117: 1370-1378.
  • 39 Toumadje A, Alcorn SW, Johnson WC. Extending Cd Spectra of Proteins to 168 Nm Improves the Analysis for Secondary Structures. Anal Biochem 1992; 200: 321-331.
  • 40 Sreerama N, Woody RW. Computation and analysis of protein circular dichroism spectra. Methods Enzymol 2004; 383: 318-351.
  • 41 Greinacher A, Alban S, Dummel V. et al. Characterization of the Structural Requirements for a Carbohydrate-Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-Associated Thrombocytopenia. Thromb Haemost 1995; 74: 886-892.
  • 42 Record Jr. MT, Lohman ML, De Haseth P. Ion effects on ligand-nucleic acid interactions. J Mol Biol 1976; 107: 145-158.
  • 43 Mascotti DP, Lohman TM. Thermodynamics of Single-Stranded Rna-Binding to Oligolysines Containing Tryptophan. Biochem Us 1992; 31: 8932-8946.
  • 44 Sperber BL, Cohen Stuart MA, Schols HA. et al. Overall charge and local charge density of pectin determines the enthalpic and entropic contributions to complexation with beta-lactoglobulin. Biomacromol 2010; 11: 3578-3583.
  • 45 Laugel N, Betscha C, Winterhalter M. et al. Relationship between the growth regime of polyelectrolyte multilayers and the polyanion/polycation complexation enthalpy. J Phys Chem B 2006; 110: 19443-19449.
  • 46 de Souza HKS, Bai GY, Goncalves MP. et al. Whey protein isolate-chitosan interactions: A calorimetric and spectroscopy study. Thermochim Acta 2009; 495: 108-114.
  • 47 Hofs B, Voets IK, de Keizer A. et al. Comparison of complex coacervate core micelles from two diblock copolymers or a single diblock copolymer with a polyelectrolyte. Phys Chem Chem Phys 2006; 08: 4242-4251.
  • 48 Tan WF, Koopal LK, Norde W. Interaction between Humic Acid and Lysozyme, Studied by Dynamic Light Scattering and Isothermal Titration Calorimetry. Environ Sci Technol 2009; 43: 591-596.
  • 49 Girard M, Turgeon SL, Gauthier SF. Quantification of the interactions between beta-lactoglobulin and pectin through capillary electrophoresis analysis. J Agr Food Chem 2003; 51: 6043-6049.
  • 50 Visentin GP, Moghaddam M, Beery SE. et al. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001; 138: 22-31.
  • 51 Leroux D, Canepa S, Viskov C. et al. Binding of heparin-dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay. J Thromb Haemost 2012; 10: 430-436.
  • 52 Whitehead MP, Eagles L, Hooley P. et al. Most bacteria synthesize polyphosphate by unknown mechanisms. Microbiol 2014; 160: 829-831.
  • 53 Arman M, Krauel K, Tilley DO. et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. Blood 2014; 123: 3166-3174.
  • 54 Greinacher A, Gopinadhan M, Gunther JUG. et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscl Thromb Vasc Biol 2006; 26: 2386-2393.
  • 55 Rauova L, Poncz M, McKenzie SE. et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
  • 56 Qiao S, Luo Q, Zhao Y. et al. Structural basis for lipopolysaccharide insertion in the bacterial outer membrane. Nature 2014; 511: 108-111.
  • 57 Strauss J, Burnham NA, Camesano TA. Atomic force microscopy study of the role of LPS O-antigen on adhesion of E. coli. J Mol Recogn 2009; 22: 347-355.
  • 58 Tan YH, Liu M, Nolting B. et al. A nanoengineering approach for investigation and regulation of protein immobilization. ACS Nano 2008; 02: 2374-2384.
  • 59 Salvaggio HL, Graeber KE, Clarke LE. et al. Mucocutaneous Granulomatous Disease in a Patient With Hermansky-Pudlak Syndrome. J Am Med Assoc Dermatol 2014; 150: 1083-1087.
  • 60 Mora AJ, Wolfsohn DM. The management of gastrointestinal disease in Hermansky-Pudlak syndrome. J Clin Gastroenterol 2011; 45: 700-702.